GNI Group to halt enrolment in Phase 2 liver fibrosis trial following positive results
Japanese biotech company GNI Group has announced it will cease enrolment of new patients in its Phase 2 liver fibrosis trial for the drug candidate F351 in China. This decision follows a recommendation from an independent data monitoring committee (IDMC) based on positive efficacy results achieved to date. As of now, 175 out of the […]